Open AccessClinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting
Author(s) -
G. Griesinger,
T. Schill,
Michael Sator,
Michael Schenk,
Jan-Steffen Krüssel
Publication year - 2021
Publication title -
journal of reproduction and infertility
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.495
H-Index - 22
eISSN - 2251-676X
pISSN - 2228-5482
DOI - 10.18502/jri.v22i2.5798
Subject(s) - intracytoplasmic sperm injection , ovarian hyperstimulation syndrome , embryo transfer , medicine , controlled ovarian hyperstimulation , follicular phase , gynecology , in vitro fertilisation , assisted reproductive technology , hormone antagonist , andrology , antagonist , pregnancy , infertility , biology , receptor , genetics
This phase IV routine care study evaluated ovarian responses when using a biosimilar follitropin alfa r-hFSH (Bemfola ® ) for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technology (ART) treatment who were pituitary-suppressed with a gonadotrophin-releasing hormone (GnRH) antagonist.